



Biodol Therapeutics announces the nomination of its first PreClinical Candidate as a next-generation stand-alone therapy for Neuropathic Pain

Montpellier, France, 31 August 2022 – Biodol Therapeutics, a French biotech company developing next-generation neuropathic pain treatments, announces nomination of its first Preclinical Candidate. The company aims to advance into IND-Enabling studies, initiating Phase 1 studies in the second half of 2023.

Neuropathic pain is a chronic condition with only few treatment options to date. Limited efficacy and debilitating side effects are common with current therapeutics. By targeting the neuro-immune interface, BIODOL Therapeutics is tackling neuropathic pain in a novel way. The compound has shown exceptional activity in a wide range of preclinical pain models, combined with an excellent safety profile.

It targets the extracellular domain of the FLT3 receptor, which is highly specific in comparison to the highly conserved intracellular domain of RTKs. BIODOL Therapeutics succeeded in identifying a selective and potent drug candidate for oral chronic administrations, without the safety limitations of less specific intracellular kinase inhibitors.

The company has gathered an extremely favorable chemical, metabolic, pharmacological and safety data package with validation in multiple pathophysiological models of neuropathic pain. Following the validation by external experts – and thanks to its Series A fundraising in 2020 with the support of V-Bio Ventures – the company can now start Regulatory Preclinical Development before entering clinical phases.

The attractive profile of the preclinical candidate enables the company to move forward and pursue its program up to its investigational new drug (IND) application. In parallel, Biodol Therapeutics is finalizing its clinical plan together with its network of medical experts. These clinical trials will be funded via a Series B round, expected in 2023.

BIODOL Therapeutics is a preclinical-stage private company developing orally bioavailable NCEs as first-in-class treatments for chronic pain disorders, targeting a key mechanism in the pathophysiology of neuropathic pain.

BIODOL Therapeutics develops innovative chronic oral administrations of small-molecule extracellular negative allosteric modulators (NAM), which block the binding of the cytokine FL to the FLT3 receptor tyrosine kinase (RTK), found to be the fundamental mechanism in the generation and chronification of neuropathic pain.

About Biodol Therapeutics

Biodol Therapeutics (www.biodol.eu), founded in 2015, develops first-in-class compounds for the treatment of chronic pain (CP). Biodol Therapeutics has identified the Receptor Tyrosine Kinase (RTK) FLT3 as a key player for triggering and maintaining the chronic neuropathic pain (NP) state. The company is focused on the development of allosteric inhibitors of the FLT3 receptor for the treatment of chronic pain. Biodol Therapeutics already owns the exclusive rights on a portfolio of 4 patents. The company has been supported by BPI France, Satt AxLR, Inserm Transfert, Region Occitanie, the French National Research Agency, SEMIA Incubator and Montpellier Business and Innovation Centre.

About V-Bio Ventures

V-Bio Ventures (www.v-bio.ventures) is an independent venture capital firm specialized in building and financing young, innovative life science companies. V-Bio Ventures was established in 2015 and works closely with Belgium-based VIB, one of the world's premier life science institutes. The fund invests throughout Europe in start-up and early-stage companies with high growth potential focusing on technologies that provide transformational improvements in the biopharmaceutical, pharmaceutical, diagnostics and agricultural sectors.

For more information, please contact:

Biodol Therapeutics
contact@biodol.eu